Asthma
Conditions
Brief summary
This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic phenotype and 2) to examine the utility of PET/CT for demonstrating that reslizumab produces a reduction in lung inflammation in participants with severe asthma and an eosinophilic phenotype .
Interventions
DRUGReslizumab
Reslizumab will be administered as per the dose and schedule specified in the arm.
DRUGFludeoxyglucose F 18 (FDG)
FDG will be administered by IV infusion prior to each PET/CT scan.
DRUGPlacebo
Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female, 18 through 50 years of age. * Females that are either surgically sterile, are 2 years postmenopausal, or have a negative pregnancy test at screening. * Females of childbearing potential (not surgically sterile or 2 years postmenopausal), have to use a medically accepted method of contraception and have to agree to continue to use of this method for the duration of the study and for 5 months after study drug administration. * Participants with less that 10-pack year history of smoking. * Have a previous diagnosis of asthma. * Participants taking inhaled fluticasone at a dosage of at least 440 micrograms (mcg) daily, or equivalent. * The participant's baseline asthma therapy must be stable for 30 days prior to screening and judged by their treating physician to be able to continue without dosage changes throughout the study. * Participants with a blood eosinophil level of at least 400 cells/microliter (cells/μL) at screening. Participants with a blood eosinophil level below 400 cells/μL will be given 2 additional screening opportunities to determine blood eosinophil levels. * Additional criteria apply; please contact the investigator for more information.
Exclusion criteria
* Participants requiring treatment with oral, intramuscular, or IV corticosteroids within 6 weeks of the Part 1 baseline visit for an asthma exacerbation. * Participants with any other confounding underlying lung disorder including but not limited to: bronchiectasis, chronic obstructive pulmonary disorder, smoking greater than or equal to (≥)10 pack year history, pulmonary fibrosis, emphysema, cystic fibrosis, and lung cancer. * Participants diagnosed with diabetes mellitus. * Participants with pulmonary conditions and blood eosinophilia other than eosinophilic asthma. * Participants with clinically meaningful comorbidity that can interfere with the study schedule or procedures, or compromise the participant's safety. * Participants that are current smokers (that is, have smoked within the last 12 months prior to screening). * Participants using systemic immunosuppressive, immunomodulating, or other biologic agents (including, but not limited to, anti-IgE mAb, methotrexate, cyclosporin, interferon-α, or anti-tumor necrosis factor mAb) within 6 months prior to screening. Participants whose treatment with anti-IgE mAb therapy (omalizumab) is considered ineffective by their physician may be included as potential participants when: 1. The omalizumab (Xolair) therapy has been discontinued. 2. The participant's blood eosinophil level meets inclusion criteria. * Participants who have previously received an anti-hIL-5 mAb (for example, reslizumab, mepolizumab \[Nucala\]) or anti-IL-5 receptor mAb (eg, benralizumab). Participants whose treatment with mepolizumab or benralizumab is considered ineffective by their physician may be included as potential participants when: 1. The mepolizumab or benralizumab therapy has been discontinued. 2. The participant's blood eosinophil level meets inclusion criteria. * Participants who had concurrent infection or disease that may preclude assessment of active asthma. * Participants with a history of concurrent immunodeficiency (human immunodeficiency virus or acquired immunodeficiency syndrome or congenital immunodeficiency). * Participants that had an active parasitic infection within 6 months prior to screening. * Participants with any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery). * Known hypersensitivity to study drug or to FDG/contrast agents * Treatment with metformin. * Compromised renal function. * Additional criteria apply; please contact the investigator for more information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1) | Baseline (Day 1) of Part 1 | GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung boundary in each axial slice. Standardized uptake value (SUV) mean and area of each ROI was recorded. Using the formula: area\*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported. |
| Part 1: Average Global Lung Glycolysis (GLG) at Day 8 | Day 8 | GLG is the total FDG uptake in the whole lung. ROI was drawn around lung boundary in each axial slice. SUV mean and area of each ROI was recorded. Using the formula: area\*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported. |
| Part 2: Change From Baseline to Week 4 in GLG | Baseline, Week 4 | — |
| Part 2: Change From Baseline to Week 4 in Lung Parenchyma (LP) SUV Mean | Baseline, Week 4 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 2: Change From Baseline to Week 4 in Blood Eosinophil Counts | Baseline, Week 4 | — |
| Number of Participants With Adverse Events (AEs) | 21 days | An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. |
| Change From Baseline to Week 4 in Forced Expiratory Volume in 1 Second (FEV1) | Baseline, Week 4 | — |
| Change From Baseline to Week 4 in Fractional Exhaled Nitric Oxide (FeNO) | Baseline, Week 4 | — |
| Change From Baseline to Week 4 in Asthma Quality of Life Questionnaire (AQLQ) Score | Baseline, Week 4 | — |
Countries
United States
Participant flow
Recruitment details
This study consisted of 2 parts: Part 1, a 21-day positron emission tomography (PET)/computed tomography (CT) screening period, and Part 2 (only participants with asthma), a 6-week double blind treatment/assessment period.
Pre-assignment details
Participants with eosinophilic asthma were to be randomly assigned 1:1 in a double-blind fashion in Part 2 of the study to receive either placebo or reslizumab. Study was terminated prior to administration of reslizumab.
Participants by arm
| Arm | Count |
|---|---|
| Part 1: PET/CT Scan Healthy participants had 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants received FDG as part of the PET/CT procedures and provided sputum/blood samples. | 5 |
| Total | 5 |
Baseline characteristics
| Characteristic | Part 1: PET/CT Scan |
|---|---|
| Age, Continuous | 32.4 years STANDARD_DEVIATION 10.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 1 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 5 |
| other Total, other adverse events | 1 / 5 |
| serious Total, serious adverse events | 0 / 5 |
Outcome results
Primary
Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1)
GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung boundary in each axial slice. Standardized uptake value (SUV) mean and area of each ROI was recorded. Using the formula: area\*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported.
Time frame: Baseline (Day 1) of Part 1
Population: All recruited healthy participants.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Part 1: PET/CT Scan | Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1) | 668.08 cubic centimeters (cm^3) | Standard Deviation 191.83 |
Primary
Part 1: Average Global Lung Glycolysis (GLG) at Day 8
GLG is the total FDG uptake in the whole lung. ROI was drawn around lung boundary in each axial slice. SUV mean and area of each ROI was recorded. Using the formula: area\*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported.
Time frame: Day 8
Population: All recruited healthy participants.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Part 1: PET/CT Scan | Part 1: Average Global Lung Glycolysis (GLG) at Day 8 | 621.71 cm^3 | Standard Deviation 208.74 |
Primary
Part 2: Change From Baseline to Week 4 in GLG
Time frame: Baseline, Week 4
Population: Part 2 of the study was not conducted, hence this outcome measure was not analyzed.
Primary
Part 2: Change From Baseline to Week 4 in Lung Parenchyma (LP) SUV Mean
Time frame: Baseline, Week 4
Population: Part 2 of the study was not conducted, hence this outcome measure was not analyzed.
Secondary
Change From Baseline to Week 4 in Asthma Quality of Life Questionnaire (AQLQ) Score
Time frame: Baseline, Week 4
Population: Part 2 of the study was not conducted, hence this outcome measure was not analyzed.
Secondary
Change From Baseline to Week 4 in Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Baseline, Week 4
Population: Part 2 of the study was not conducted, hence this outcome measure was not analyzed.
Secondary
Change From Baseline to Week 4 in Fractional Exhaled Nitric Oxide (FeNO)
Time frame: Baseline, Week 4
Population: Part 2 of the study was not conducted, hence this outcome measure was not analyzed.
Secondary
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.
Time frame: 21 days
Population: All recruited healthy participants.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1: PET/CT Scan | Number of Participants With Adverse Events (AEs) | Any AEs | 1 Participants |
| Part 1: PET/CT Scan | Number of Participants With Adverse Events (AEs) | SAEs | 0 Participants |
Secondary
Part 2: Change From Baseline to Week 4 in Blood Eosinophil Counts
Time frame: Baseline, Week 4
Population: Part 2 of the study was not conducted, hence this outcome measure was not analyzed.